Early this year, The ALS community was saddened by the results of Biogen’s phase III clinical trial of dexpramipexole and disappointed in the company’s announcement that it will discontinue development of the drug. Was there any good news to come out of the trial?
The ALS Association’s Chief Scientist Lucie Bruijn spoke with Biogen’s Douglas Kerr, M.D., Ph.D., Director of Neurodegeneration, Clinical Research, about the company’s ongoing commitment to ALS and how this trial does in fact contribute to the search for treatments and a cure for Lou Gehrig’s disease.
Click play to listen to their conversation:
Read more about dexpramipexole: http://www.alsa.org/news/media/press-releases/biogen-discontinues-dexpram.html